Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany

Tools

Item Type:	Article
Title:	Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany
Creators Name:	Liu, J., Mori, M., Zimmermann, H., Brandt, A., Havla, J., Tanaka, S., Sugimoto, K., Oji, S., Uzawa, A., Asseyer, S., Cooper, G., Jarius, S., Bellmann-Strobl, J., Ruprecht, K., Siebert, N., Masuda, H., Uchida, T., Ohtani, R., Nomura, K., Meinl, E., Kuempfel, T., Paul, F. and Kuwabara, S.
Abstract:	BACKGROUND: Neurological disorders with IgG antibodies against myelin-oligodendrocyte glycoprotein (MOG-IgG) have been increasingly recognised as a new type of neuroinflammatory disorder. OBJECTIVE: The study aimed to identify regional and ethnic differences in clinical profiles of MOG-IgG-associated disorders between East Asian (Japanese) and Caucasian (German) patients. METHODS: Demographic, clinical and therapeutic data from 68 MOG-IgG-positive adults were collected (Japanese, n=44; German, n=24). RESULTS: Age and sex were similar between cohorts, with optic neuritis occurring most frequently at onset (Japanese: 61%; German: 58%). However, Japanese patients had a lower annualised relapse rate (0.4 vs 0.8, p=0.019; no relapse, 64% vs 25%, p=0.002) and lower Expanded Disability Status Scale score at the last visit (1.0 vs 2.0; p=0.008), despite similar follow-up periods (mean, 73.9 months vs 73.4 months), than those of German patients, respectively. Cerebral syndromes were more common (27% vs 4%; p=0.021) and myelitis less common (21% vs 50%; p=0.012) in Japanese than in German patients, respectively. Japanese patients were more commonly treated with long-term corticosteroids (73%), whereas German patients were more commonly treated with rituximab or other immunosuppressants (63%). CONCLUSIONS: Among patients with MOG-IgG, Japanese tended to have a monophasic milder disease, whereas the majority of German patients had a relapsing course and more frequent myelitis, findings compatible with neuromyelitis optica spectrum disorder. Although the attack-prevention treatment regimens were considerably different, genetic and environmental factors may be important to determine clinical phenotypes and disease activity.
Source:	Journal of Neurology Neurosurgery and Psychiatry
ISSN:	0022-3050
Publisher:	BMJ Publishing Group
Volume:	92
Number:	4
Page Range:	377-383
Date:	April 2021
Official Publication:	https://doi.org/10.1136/jnnp-2020-324422
PubMed:	View item in PubMed

Repository Staff Only: item control page